Index

acceptable macronutrient distribution range (AMDR), 496, 497, 498
AD, see atopic dermatitis (AD)
adverse food reaction, see food allergy
albumin, 453
aldehyde dehydrogenase (ALDH), 445
ALDH, see aldehyde dehydrogenase (ALDH)
Alexandrium catenella, 512, 526
Alexandrium tamarense, 526
alimentary toxic aleukia (ATA), 513
allergens
nutrient content, 501
allergen-nonspecific therapy, 592–4
humanized monoclonal anti-IgE, 592
traditional Chinese medicine, 592–4
allergens in OAS, 159–60
peanut, 164
unexpected sources, 455
See also food allergens
allergen-specific IgG4, 550
allergic contact dermatitis (ACD), 136, 246
food-induced, 137
laboratory tests, 256
allergic inflammation, 22–3, 23
Allergy Society of South America (ALLSA), 328
ALLSA, see Allergy Society of South America (ALLSA)
ALSPAC, see Avon Longitudinal Study of Parents and Children (ALSPAC)
altered intestinal permeability
and gut antigen handling, 574–5
Anemia megaloblastica, 514
Anemia thalassemia, 514
anemia, 514
AMOK, see acceptable macronutrient distribution range (AMDR)
American Academy of Allergy Asthma and Immunology (AAAAI), 328
ammonium caseinate, 453
ammonial shellfish poisoning, 512, 528–9
anaphylaxis, 178
anaphylactoid, 178
anaphylaxis, 178–88
activation of mast cells, 185
β-adrenergic antagonists, 183
affected skin, 185
asthma as risk factor for, 173
biphasic, 178
definition, 178–9
delayed, 177
diagnosis, 183–5
diagnostic criteria, 179
laboratory evaluation, 183–5
erythema, 181–3
food additives, 180
foods, 181–2
food-associated and exercise-induced, 137, 177, 180–81
laryngospasm, 184
overdose, 178
prevalence, 124, 179–81
prognosis, 180
urticaria, 178
symptomatic survey, 179–80
sense of doom, 183
treatment, 185–8
acute management, 185–7
long-term management, 187, 187–8
unstable
food allergy
anaphylaxis-like events, 562
animal models
for human gastrointestinal tract, 551–2
IgE-mediated food allergy, 547–9
gastrointestinal manifestations model, 549
large animal models, 549
oral sensitization, 547–9
amino acids, 319–20
ammonia, 353
anti-dendritic cell, 355
arginine kinase, 38
ASCA, see Australasian Society of Clinical Immunology and Allergy (ASCIA)
Aspergillus fumigatus, 253
asthmatic exacerbation respiratory disease (AERD), 469
asthma, 140
association with amitrazine, 366–9
baker’s, 171
childhood, 172–3
epidemiology, 341–2
food allergy as risk factor for, 172–3
relationship with food allergy, 173
as risk factor for anaphylaxis, 173
Atkins diet, 542
atopic dermatitis (AD), 140
allergens of, 145
apomorphine patch testing, 269–80
cytokines secreted in, 144–5
food allergy associated with, 145
diagnosis of, 150, 150–52
epidemiology of, 146–50
role of, 145–9
IgE levels in patients with, 145
IgE serotyping, 466
management of, 152–5
overview, 144
pathophysiology, 144–5

Index

atopic dermatitis (AD) (Continued) prevention through diet, 146–7
Scabies excreta, 335
atopy patch testing (APT), 289–93
for AD, 149
assessing, 292
avoidance prior to, 295
conditions, 295
ETAP grading, 292
for food hypersensitivity, 151–2
food protein-induced enterocolitis syndrome, 235
history, 289
atopic dermatitis, 289–90
cosmopolitan eczematoid, 290–91
TPEIS, 291–2
interpretation, 292–3
overview, 289
Australian Society of Clinical Immunology and Allergy (ASCIA), 328
autoimmune spectrum disorders (ASDs), 560
Ayon Longitudinal Study of Parents and Children (ALSPAC), 476
AZA, azaspiracids (AZA), 530
azaspiracid shellfish poisoning, 530
azaspirazines (AZA), 530
Bacillus coagulans, 530
azaspiracid shellfish poisoning, 530
azaspiracids (AZA), 530
see also
ciguatoxins (CTX), 523–4
breast-fed infants vs formula-fed infants, 195
vs formula-fed infants, 194, 194–5
breast milk
dairy proteins in, 479
source of immune-regulating substances, 479–80
brevetoxins (BTX), 327
bronchoalveolar lavage (BAL), 256
RTX, or brevetoxins (BTX)
butyryl coenzyme A hydrolase (BHA), 352
butyrylhydroxylamine (BHA), 352
caffeine, 446
adverse effects, 445–4
Chinese asymptomatic, 335
Cordal hypersensitivity syndrome, 335
CAPS, or Childhood Asthma Prevention Study (CAPS)
caprylic acid, 446–5, 446
adverse pharmacologic effects, 445
burning oral sensation, 444–5
Gapsilact, 444
CAPS-System Fluorescent-enzyme immunoassay
(PFEIA), 151
carbohydrates, 496
carbohydrases, 498
carboxyfluorescein succinimidyl ester (CFSE), 415
chemical structures, 415
commercial uses of carminic/cochinsial extract, 415
cimetidine, 548
CD4+ T cells in food-protein-induced enterocolitis syndrome, 235
CD4+ T cells
allergy in, 224–5
treatment, 224–5
treatment for eosinophilic esophagitis, 206
for eosinophilic esophagitis, 205
T cells in, 219
risk in relatives, 226
refractory, 226
psychological disorders, 560
gastrointestinal, 446
clinical, 446
for eosinophilic esophagitis, 205
corticosteroids, 446
Cysl (Cu,Fe), 527
cholera toxin, 548
cinnamon poisoning, 511–12, 521–4
cinnamonosins (CTN), 523–4
Gastric cards, 511
clinical history, 507–9
amounts of food, 509
suspected food, 509
Glutamine difficult, 513
Glutamin pyroglutamic, 571
Granular, 415
coffee worker's lung, 249
commercial food products, 317–18
complementary feeding, 479
for infant, 479–82
component-resolved diagnostics, 619
Consortium of Food Allergy Research (CoFAR), 495
cross-sensitization, 402–4
eczema, 193
in food allergy, 193
neonatal, 193
symptoms, 193
spontaneous, 193
non-IgE-mediated, 198
non-IgE-mediated disease, 198
cylindrin sodium
for eosinophilic esophagitis, 205
cortisone, 514
Cuminum cyminum, 514
complementary for cosmetic use, 206
for rhinitis, 514
see also
concomitants, 156
complementary for cosmetic use, 206
for rhinitis, 514
natural occurrence, 511–13
and occupational diseases, 250
cooking, 456
copper poisoning, 510
cranes, 514
cupins, 54
cross-reacting food allergens, 320–24
cross-reactive carbohydrate determinants (CCDs), 160
cross-sensitization, 402–4
crying syndromes, 193
See also infantile colic
CHE, see cytostatics (CTN)
coriander, 54

600
cutaneous adverse reactions, 162
cyanogenic glycosides, 114
cysteine proteases, 37
cysteinyl leukotriene testing, 151
Dactylopius coccus costa, 413
DBPCFC study, see double-blind, placebo-controlled food challenge (DBPCFC) study
delayed-type (IV) hypersensitivity, 347–8
De Heris Antiepileptic Darbep, 251
dermatitis herpetiformis (DH), 137–8, 222
dermatitis herpetiformis pemphigoidosis, 252
desensitization, vs oral tolerance, 583–4
dermatitis herpetiformis (DH), 137–8, 222
dermititis herpetiformis pemphigoidosis, 252
desensitization, vs oral tolerance, 583–4
diagnosis and Rationale for Action against Cow’s Milk Allergy (DRAcMA), 500
diagnostic test
for food allergy, 129
diabetes crivitil (DAC), 440
diabetic shellfish poisoning, 512, 529–30
diet, 492–505
diet, 492–505
dietary sources
of minerals and trace elements, 502
of vitamins, 501
of minerals and trace elements, 502
of vitamins, 501
digestive enzymes, 528
diet and Traveling with Food Allergy, 462
diabetes, 512
disease modifying antihistaminic agents (DMMAs) for rheumatoid arthritis, 569, 571
DMMAs, see disease modifying antihistaminic agents (DMMAs)
Dose-Adjusted Epirubicin to Optimize Mother Infant Outcomes (DAMEMI) study, randomized controlled trial, 486
dose Diet, 571
dose, 444
double-blind, placebo-controlled food challenge (DBPCFC) study
of elimination diet, 146
for histamine in food hypersensitivity, 148
of oral food challenge, 146
double-blind, placebo-controlled OFC (DBPCOFC), 302
DRAcMA, see Diagnosis and Rationale for Action against Cow’s Milk Allergy (DRAcMA)
EAACI, see European Academy of Allergy and Clinical Immunology (EAACI)
dietary reference intakes in infants, 496
in breast milk, 479
estimated energy requirement (EER), 496
estimate average requirement (EAR), 496
essential fatty acid (EFA)
esophagitis, 40
Escherichia coli,
ergotism, 513
epitopes, IgE-binding, 273
eosinophils, 26
eosinophilic proctocolitis (EoP), 210–12
eosinophilic gastroenteritis (EoG), 139, 208–10
enzyme-gastric, 209
clinical features, 209
definition, 208
diagnosis, 209
differential, 208
epidermis, 209
in infants, 209
laboratory evaluation, 209–10
prevalence, 209
treatment, 210
cosmopolitan distribution (EoG), 210–12
characteristics, 211
clinical manifestations, 211
definition, 211
diagnosis, 211–12
epstein, 211
laboratory evaluation, 212
and maternal breast milk, 211
prevalence, 210
long-term management, 212
cosmopolitan, 26
natural history, 210
epilepsy, 536
oligoantigenic, 537
maternal, 297–8, 571–2
elimination, 297–8
baked milk and egg, 501–502
Atkins, 542
rotation, 333
role in migraine, 536
disease modifying antirheumatic agents (DMARD)
diabetic, 513
maternal elimination,
maternal, 478–9
elimination, 297–8
of elimination diet, 146
of vitamins,
of minerals and trace elements,
recommended dietary allowance, 496
for dietary fat and EFAs in infants,
adequate intake, 496
dietary reference intakes for,
in breast milk, 479
diabetic, 502
rheumatoid arthritis, 571–2
historical background, 296–7
types, 297, for egg diet
historical background, 296–7
types, 297
in AD patients, 148
diegetic bacterium, 114
biopsy of duodenal mucosa,
cytotoxic mononuclear cells in, 238
mononuclear cells in, 238
food proteins-induced, 138, 236–9
granulocytes in in patients with, 237
cytotoxic mononuclear cells in, 238
food proteins-induced, 138, 236–9
gastrointestinal symptoms, 118
prevalence, 121
disease modifying antirheumatic agents (DMMAs)
esthesin
alloprotein pre-circuits, 19
cysteinyl leukotriene receptor (CysLT1) levels in AD patients, 148
cysteinyl leukotriene receptor (CysLT1), 139, 203–4
allergy testing, 205
asthmatic patch testing, 201–91
clinical symptoms, 204, 204
definition, 203
diagnosis, 204–5
differential, 204
upper endoscopy, 205
etiology, 203–4
incidence and prevalence, 203
and infantile colic, 196
prevalence, 124
thymic stromal lymphopoietin in, 204
treatment, 200–6
acute management, 200–6
comorbidities, 206
cromolyn sodium, 206
dietary therapy, 207
elemental diet, 207
long-term management, 208
moodles, 206
cosmopolitan gastroses (EoG), 139, 208–10
enzyme-gastric, 209
clinical features, 209
definition, 208
diagnosis, 209
differential, 208
epilepsy, 209
in infants, 209
laboratory evaluation, 209–10
prevalence, 209
treatment, 210
cosmopolitan distribution (EoG), 210–12
characteristics, 211
clinical manifestations, 211
definition, 211
diagnosis, 211–12
etiology, 211
laboratory evaluation, 212
and maternal breast milk, 211
prevalence, 210
long-term management, 212
cosmopolitan, 26
modifiers of, 24
epitaxium immunotherapies (EPTI), 189
epidermal keratinocytes in AD, 145
epigenetics, 130
epilepsy, 541–2
criteria, 541
diet manipulation in, 542
and migraine, 542
epilepsy, 549
for ammonia, 185–7, 186
epitopes, IgG-binding, 271
etiology, 513
fidgets, 581
epitopes, 40
essential fatty acid (EFA) deficiency, 497–9
dietary reference intakes in infants, 497
estimates average requirement (EAR), 496
estimated energy requirement (EER), 496
ETFAc, see European Task Force on Atopic Dermatitis (ETFAc)
etanol, 445, 466
European Academy of Allergy and Clinical Immunology (EAACI), 328

Index
health-related quality of life (HRQOL), 557–8
mercury, 511
metabolic food disorder(s), 515–16
facts, 515–16
lactose intolerance, 515
naturally occurring chemicals, 511–15
contaminants, 513–15
contaminants, 511–13
overviews, 507–8
PCR and PBI, 510–11
synthetic chemicals, 508–11
agricultural chemicals, 509–10
food additives, 508–9
industrial chemicals, 510–11
migration from packaging and containers, 510
nicam, 508
sorbital, 508
soy poisoning, 508–9
ventilatory drugs and antibiotics, 510
formula-fed infants
breast-fed infants vs. 138, 194–5
FPIES, ar, food protein-induced enterocolitis syndrome (FPIES)
fresh food skin prick tests (FSPPTs), 151
Fogo, 512
fungicides
toxicology, 509
Fusarium
gal, 137
Ganoderma lucidum, 523
Gastroenterocolitis
Gastroenteritis, 40
Gambierdiscus toxicus,
Galactose-
Fusarium
fungicides
Fugu,

Fresh food skin prick tests (FFSPTs), 151
FPIES,
breast-fed infants vs,

Veterinary drugs and antibiotics, 510

industrial chemicals, 511
migration from packaging and containers, 510
nicam, 508
sorbital, 508
soy poisoning, 508–9
ventilatory drugs and antibiotics, 510
formula-fed infants
breast-fed infants vs. 138, 194–5
FPIES, ar, food protein-induced enterocolitis syndrome (FPIES)
fresh food skin prick tests (FSPPTs), 151
Fogo, 512
fungicides
toxicology, 509
Fusarium
gal, 137
Ganoderma lucidum, 523
Gastroenterocolitis
Gastroenteritis, 40
Gambierdiscus toxicus,
Galactose-
Fusarium
fungicides
Fugu,

Fresh food skin prick tests (FFSPTs), 151
FPIES,
breast-fed infants vs,

Veterinary drugs and antibiotics, 510

industrial chemicals, 511
migration from packaging and containers, 510
nicam, 508
sorbital, 508
soy poisoning, 508–9
ventilatory drugs and antibiotics, 510
formula-fed infants
breast-fed infants vs. 138, 194–5
FPIES, ar, food protein-induced enterocolitis syndrome (FPIES)
fresh food skin prick tests (FSPPTs), 151
Fogo, 512
fungicides
toxicology, 509
Fusarium
gal, 137
Ganoderma lucidum, 523
Gastroenterocolitis
Gastroenteritis, 40
Gambierdiscus toxicus,
Galactose-
Fusarium
fungicides
Fugu,

Fresh food skin prick tests (FFSPTs), 151
FPIES,
breast-fed infants vs,

Veterinary drugs and antibiotics, 510

industrial chemicals, 511
migration from packaging and containers, 510
nicam, 508
sorbital, 508
soy poisoning, 508–9
ventilatory drugs and antibiotics, 510
formula-fed infants
breast-fed infants vs. 138, 194–5
FPIES, ar, food protein-induced enterocolitis syndrome (FPIES)
fresh food skin prick tests (FSPPTs), 151
Fogo, 512
fungicides
toxicology, 509
Fusarium
gal, 137
Ganoderma lucidum, 523
Gastroenterocolitis
Gastroenteritis, 40
Gambierdiscus toxicus,
Galactose-
Fusarium
fungicides
Fugu,

Fresh food skin prick tests (FFSPTs), 151
FPIES,
breast-fed infants vs,

Veterinary drugs and antibiotics, 510

industrial chemicals, 511
migration from packaging and containers, 510
nicam, 508
sorbital, 508
soy poisoning, 508–9
ventilatory drugs and antibiotics, 510
formula-fed infants
breast-fed infants vs. 138, 194–5
FPIES, ar, food protein-induced enterocolitis syndrome (FPIES)
fresh food skin prick tests (FSPPTs), 151
Fogo, 512
fungicides
toxicology, 509
Fusarium
gal, 137
Ganoderma lucidum, 523
Gastroenterocolitis
Gastroenteritis, 40
Gambierdiscus toxicus,
Galactose-
Fusarium
fungicides
Fugu,

Fresh food skin prick tests (FFSPTs), 151
FPIES,
breast-fed infants vs,
Index

hypersensitivity pneumonitis (Continued) 218
inhalation challenges, 218
labouratory tests, 256
smoking, and, 248
hypolipidogenic formulas 441, 552
in infantile colic treatment, 197, 198
idiosyncratic environmental intolerance (IEI), 541
IgA antibodies
food protein-induced enterocolitis syndrome, 216
IgE-dependent allergic reactions, 25
IgE, peptide-specific, 273–4
IgE-mediated reactions
food protein-induced enterocolitis syndrome, 236
IgE-binding epitopes, 273
IgE-mediated food allergy
for food allergy treatment, 581
allergen-specific, 581–3
mechanism, 105
introduction, 100
effector mechanisms, 102–3
route of sensitization, 16–17
genes and environment, 20–21
B-cell response, 18, 18
allergen-specific, 19–20
mucous membrane, 18
T-cell response, 17–18
B-cell response, 21–23
B-cell receptors, 20, 21
IgE antibodies, 332–5
food protein-induced enterocolitis syndrome, 216
immunologic assessment, 103
effector mechanisms, 102–1
factors affecting development of, 103–5
introduction, 100
mediation, 105
site of tolerance induction, 105–2
immune wild phase allergen chip (ISAC), 550
immunotherapy
allergen-specific, 581–1
approaches to, 582
baked milk and egg diet, 581–3
for food allergy treatment, 581
with modified recombinant engineered food proteins, 591, 591–2
and, 585–6
with pollen for cross-reactive food, 585
subcutaneous, 585. See also specific types of immunotherapy
inappropriate tests, 312–3
IgE antibodies, 312–3
lymphocyte subset counts, 533
pulmonary test, 533
inappropriate therapy, 314–6
Causale hypersensitivity syndrome, 335
clinical ecology, 154–5
elimination diets, 355–6
multiple chemical sensitivity syndrome, 336
indispensable amino acids (AAAs), 497
Individualized Health Care Plan (IHP), 489
infant feeding practices, 127–8
infantile colic, 192–8
behavior interventions, 194
dietary treatment, 197–8
hypersensitivity pneumonitis, 197
maternal elimination diets, 197, 197–8
diurnal variation to distress scores, 191
epidemiology, 192–3
factors associated with, 193–5
infantile factors, 195–6
maternal factors, 194
and food allergy
breast-fed infants, 195
breast-fed vs formula-fed infants, 196, 194–5
and cow’s milk allergy, 194
development of, 193
investigation and management in suspected, 198
and gastrointestinal disorders, 195–7
gastrointestinal reflux and esophagitis, 195–6
intestinal spasm, 196
lactase maltase, 196–7
and intestinal microbiota, 195
overview, 192
parental support, 194
prevalence, 193
inflammatory dendritic epidermal cells (IDECs) in AD, 145
infections
food toxicology, 509
intestinal microbial flora
RA and alterations in, 173–4
intestinal microflora
inflammasome with colic, 195
intestinal spasm, 196
intraepithelial skin tons
amylase, 184–5
intraepithelial lymphocytes, 224
in vitro allergen-specific IgG testing, 310
in vitro diagnosis, 265–74
IIc cell responses to food allergy, 550
component-resolved diagnosis, 272–4
of food allergy, 309–11
overview, 269
quantitative measurement, 269–72
in vitro diagnosis, 278–85
elimination diets, 284–5
history and physical examination, 283–4
oral food challenges (OCF), 284–5
additional diagnostic steps prior, 283
issues, 285
overview, 278
serum food-specific IgE antibodies, 283
skin prick tests (SPT), 278–83
advantages and pitfalls, 283–4
diagnostic accuracy, 281
diagnostic value, 240–41
impact sensitivity, 280
predictive value, 282
receiver operator curve, 281
risks of, 281–2
technical considerations, 279–80
intolerance, 352
iron deficiency anemia, 219
vs PPIEs, 231
immune contact dermatitis (ICD), 246
ISAC, see immune wild phase allergen chip (ISAC)
Kaplan–Meier analysis
soy allergy, 471
Keratin 85, 527–8
Klebsiella pneumoniae, 441, 552
KLH, see keyhole limpet hemocyanin (KLH)
Label Declaration of Allergenic Substances in Foods, 454
labeled (food)
cross-contam during food processing, 455–6
and food allergy, 453–5
Lactobacillus acidophilus, 485
Lactobacillus casei, 126
Lactobacillus lactis, 199
Lactobacillus rhamnosus, 576
Lactobacillus reuteri, 524
Lactic acid (LA), 448
Langerhans cells (LCs)
in AD lesions, 145
Langerhans cell histiocytosis, 144
Larval-sting syndrome, 162
LCPUFAs, see long-chain polyunsaturated fatty acids (LCPUFAs)
lead exposure, 510
Learning Early About Peanut Allergy study, 483
licorice, 448
linoleic acid (LA), 448
metabolism, 474, 575
lipid transfer proteins (LTPs), 160
lipid transfer protein syndrome, 161–2
Leishmania monocytose, 549
long-chain polyunsaturated fatty acids (LCPUFAs), 405–6
lower respiratory tract infections (LRTI), 480
LRTI, see lower respiratory tract infections (LRTI)
lymphocyte subset counts, 533
occupational dermatitis, 245
in baker, 251
in food processing, 251
prevalence and incidence, 247
occupational diseases, 245–61
agents associated with, 248–51
challenges, 237–8
classifications, 246
definition, 246
diagnosis, 254–7
history and physical examination, 254–5
laboratory tests, 254–6
pulmonary function testing, 257
exposure routes, 254–5
food additives and contaminants, 250
mushroom worker’s lung, 253
overview, 245
prevalence and incidence, 246–7
prevention and treatment, 260–61
prognosis, 258–60
risk factors, 247–8
aroma, 247–8
bronchial responsiveness, 248
genetic susceptibility, 248
smoking, 248
See also specific occupational diseases
Occupational Physicians Reporting Activity (OPRA), 247
occupational rhinitis
oral food challenge (OFC), 284–5, 298–303
oral allergy syndrome (OAS), 136, 158–65,
oligoantigenic diet, 297, 537
oleocanthal, 448–9
OFC, occupational rhinitis
Occupational Physicians Reporting Activity (OPRA), 247
oral food challenge (OFC), 284–5, 298–303
oral allergy syndrome (OAS), 136, 158–65,
oligoantigenic diet, 297, 537
oleocanthal, 448–9
OFC, occupational rhinitis
oral food challenge (OFC), 284–5, 298–303
oral allergy syndrome (OAS), 136, 158–65,
oligoantigenic diet, 297, 537
oleocanthal, 448–9
OFC, occupational rhinitis
oral food challenge (OFC), 284–5, 298–303
oral allergy syndrome (OAS), 136, 158–65,
oligoantigenic diet, 297, 537
oleocanthal, 448–9
oral food challenge (OFC), 284–5, 298–303
oral allergy syndrome (OAS), 136, 158–65,
oligoantigenic diet, 297, 537
oleocanthal, 448–9
oral food challenge (OFC), 284–5, 298–303
oral allergy syndrome (OAS), 136, 158–65,
oligoantigenic diet, 297, 537
oleocanthal, 448–9
oral food challenge (OFC), 284–5, 298–303
oral allergy syndrome (OAS), 136, 158–65,
oligoantigenic diet, 297, 537
oleocanthal, 448–9
oral food challenge (OFC), 284–5, 298–303
oral allergy syndrome (OAS), 136, 158–65,
Index

- trachealization, 205
- Traditional Chinese Medicine (TCM), 592–4
- transient receptor potential channel A1 (TRPA1), 448
- tree nuts allergy, 503–4
- natural history, 471
- tropomyosins, 48
- TSLP, see thymic stromal lymphopoietin (TSLP)
- TTX, see tetrodotoxins (TTX)
- tumor necrosis factor (TNF), 573
- in food protein-induced enterocolitis syndrome, 235–6
- tyramine, 442, 466
- unpasteurized milk, 484–5
- unproven tests, 320–32
- body chemical analysis, 352
- cytotoxic leukocyte testing, 352
- definition, 329
- electrodiagnosis, 311–2
- hair analysis, 312
- kinesiology, 329–30
- neutralization therapy, 331
- overview, 328
- provocative testing and neutralization, 510–51
- radon, 352
- unproven therapy, 335–4
- mercury amalgam removal, 534
- neutralization therapy, 333
- orthomolecular therapy, 333–4
- reflexology, 354
- rotation diets, 335
- urine autoinjections, 354
- vasoactive amines (histamine), 439–41, 466
- vagal syncope, 104
- weight loss, 573
- wheat allergy, 502–3
- soy, 453
- yessotoxin (YTX), 529
- YTX, see yessotoxin (YTX)
- zinc intoxication, 510

vitamin
- dietary sources of, 501
- supplementation, 466–7
- role in food allergy, 128–9
- weight loss, 573
- wheat allergy, 502–3
- soy, 453
- yessotoxin (YTX), 529
- YTX, see yessotoxin (YTX)
- zinc intoxication, 510